GlaxoSmithKline Vaccine Facility to be Built at Texas A&M
A new biopharmaceutical manufacturing facility will be created in College Station.
Texas Governor Rick Perry was joined by Texas A&M System Chancellor John Sharp and GlaxoSmithKline Vaccines Senior Vice President Antoon Loomans on Tuesday to announce a major partnership creating a state-of-the-art influenza-vaccine manufacturing facility.
The $91 million facility will anchor the Texas A&M Center for Innovation in Advanced Development and Manufacturing.
“Not only will this center keep Americans safer from epidemic, it will bring in more than $41 billion to the state over the next 25 years and contribute to the creation of more than 6,800 jobs in Texas,” said Perry.
“GSK is privileged to deepen our commitment to U.S. public health, as part of this unprecedented public-private collaboration to protect against pandemics and bio-threats,” said Loomans. “In Texas A&M we have found a partner with a rich tradition of service, and with pioneering technologies that will benefit the entire pharmaceutical industry in making vaccines available and accessible to all in need.”